MAPK
Le MAPK sono una famiglia di chinasi proteiche coinvolte in una varietà di processi cellulari, tra cui crescita, proliferazione, differenziazione e risposte allo stress. La via di segnalazione MAPK è composta da diversi livelli, tra cui ERK, JNK e p38 MAPK, ciascuno con ruoli distinti nella funzione cellulare. La disregolazione della segnalazione MAPK è collegata al cancro, alle malattie infiammatorie e ai disturbi metabolici. Presso CymitQuimica, offriamo una vasta gamma di inibitori e attivatori delle MAPK per supportare la tua ricerca in biologia cellulare, trasduzione del segnale e meccanismi delle malattie.
Trovati 894 prodotti di "MAPK"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
SR-302
CAS:<p>SR-302 is a potent and selective inhibitor of DDR/p38, with IC50 values of 0.125 μM for p38α, 0.023 μM for DDR1, and 0.018 μM for DDR2. It is utilized in research related to fibrotic diseases, such as kidney and lung fibrosis, atherosclerosis, and various types of cancer.</p>Formula:C32H42N6O5SColore e forma:SolidPeso molecolare:622.778(R)-STU104-d6
CAS:(R)-STU104-d6 is a deuterium-labeled variant of (R)-STU104. This compound acts as a potent and orally active inhibitor of the interaction between TAK1 and MKK3 proteins, exhibiting IC50 values of 0.58 μM for TNF-α and 4.0 μM for MKK3 phosphorylation. By binding to MKK3, (R)-STU104 hinders TAK1's ability to phosphorylate MKK3, thereby disrupting the TAK1/MKK3/p38/MnK1/MK2/elF4E signaling pathway. It is utilized in research related to ulcerative colitis.Formula:C18H182D6O4Colore e forma:SolidPeso molecolare:304.37MRTX-EX185
<p>MRTX-EX185 inhibits GDP-KRAS/G12D; IC50=90 nM on G12D. It also binds GDP-HRAS.</p>Formula:C33H33FN6O2Colore e forma:SolidPeso molecolare:564.65KRASG12C IN-15
CAS:<p>KRASG12C IN-15 (Compound 21) is an orally active KRASG12C inhibitor that effectively blocks SOS1-mediated GDP/GTP exchange with an IC50 of 19 nM. It inhibits ERK phosphorylation with an IC50 of 0.051 μM and reduces the viability of KRASG12C mutant MIA PaCa-2 cells with an IC50 of 0.023 μM. Additionally, KRASG12C IN-15 demonstrates antitumor activity in a MIA PaCa-2 xenograft mouse model.</p>Formula:C31H32FN3O2Colore e forma:SolidPeso molecolare:497.603KRAS G12C inhibitor 37
CAS:KRAS G12C inhibitor 37 targets a key signaling protein, showing promise for cancer research involving KRAS G12C.Formula:C35H39F3N8O2Colore e forma:SolidPeso molecolare:660.73(rel)-AR234960
CAS:(rel)-AR234960 is an active relative configuration of AR234960. AR234960 is a non-peptide agonist of MAS.Formula:C27H30FN5O5SColore e forma:SolidPeso molecolare:555.63p38 MAPK-IN-6
CAS:<p>p38 MAPK-IN-6 (compound c47) is an inhibitor of p38 MAPK, exhibiting a 14% inhibition rate at a concentration of 10 μM.</p>Formula:C16H14BrN3OS2Colore e forma:SolidPeso molecolare:408.336JH295 hydrate
JH295 hydrate: potent, irreversible Nek2 inhibitor (IC50 = 770 nM), selective, doesn't target Cdk1, Aurora B or Plk1.Formula:C18H18N4O3Colore e forma:SolidPeso molecolare:338.36JD118
CAS:<p>JD118 is an inhibitor of JNK. It effectively suppresses the activity of JNK1 and the expression of cJun (1 - 135).</p>Formula:C13H12N4S2Colore e forma:SolidPeso molecolare:288.391JNK-1-IN-5
CAS:JNK-1-IN-5 (Compound 14) is a potent JNK1 inhibitor with sub-nanomolar efficacy. It effectively inhibits TGF-β-induced epithelial-mesenchymal transition and shows promise for research targeting JNK1 as an anti-pulmonary fibrosis agent.Formula:C23H21BrN6O3Colore e forma:SolidPeso molecolare:509.355XMU-MP-9
CAS:XMU-MP-9, a bifunctional compound, targets the C2 domain of Nedd4-1 and the allosteric site of K-Ras. It enhances the interaction and induces conformational changes within the Nedd4-1/K-Ras complex. Furthermore, XMU-MP-9 facilitates the ubiquitination and degradation of various K-Ras mutants and inhibits the proliferation of cells with these mutants. This compound is useful in cancer research.Formula:C19H13ClFN3OSColore e forma:SolidPeso molecolare:385.84SOS1 activator 2
CAS:<p>SOS1 activator 2 (Compound 65) is a benzothiazole derivative and an activator of SOS1. It demonstrates a high binding affinity for SOS1, with a Kd of 9 nM. By modulating the Ras-ERK signaling pathway, SOS1 activator 2 is suitable for tumor research.</p>Formula:C26H28ClFN6Colore e forma:SolidPeso molecolare:478.992p38 Kinase inhibitor 8
CAS:<p>p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.</p>Formula:C22H21FN6O2Colore e forma:SolidPeso molecolare:420.44p38α inhibitor 8
CAS:p38α inhibitor8 (Compound 1) demonstrates inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.21 µM and 0.202 µM, respectively.Formula:C17H13FN6Colore e forma:SolidPeso molecolare:320.324p38 Kinase inhibitor 7
CAS:p38 Kinase inhibitor 7 (Comp:XXXIX) is an inhibitor of p38α, with an IC50 value of 5.25 nM. It also effectively suppresses TNFα production in THP-1 cells, demonstrating an IC50 of 5.88 nM.Formula:C22H25FN6OColore e forma:SolidPeso molecolare:408.472p38 MAP Kinase-IN-1
CAS:<p>p38 MAP Kinase-IN-1 (Compound 4) is an inhibitor of p38, suitable for studies related to inflammation and autoimmune responses.</p>Formula:C20H19FN6OColore e forma:SolidPeso molecolare:378.403Casein kinase 1δ-IN-27
CAS:<p>Casein kinase1δ-IN-27 (Compound 8) is an inhibitor of casein kinase 1 (CK1), effectively inhibiting CK1α, CK1δ, CK1ε, and p38α with IC50 values of 22, 16.5, 9.41, and 14.8 nM, respectively. It also suppresses DUX4 expression, with an IC50 of 10 nM.</p>Formula:C21H19FN6Colore e forma:SolidPeso molecolare:374.414JNK-IN-21
CAS:<p>JNK-IN-21 (Compound 62) is an inhibitor of JNK-1.</p>Formula:C19H16N2O2SColore e forma:SolidPeso molecolare:336.408KRAS G12C inhibitor 15
CAS:<p>KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor .</p>Formula:C25H21ClF2N4O3Purezza:98%Colore e forma:SolidPeso molecolare:498.91CK1δ-IN-9
CAS:CK1δ-IN-9 (Compound 8) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ with an IC50 of 1.4 nM. The compound also inhibits p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 exhibits favorable pharmacokinetic properties, including high oral bioavailability (70%) and moderate clearance.Formula:C16H12FN5Colore e forma:SolidPeso molecolare:293.298
